Wall Street analyst estimates for Grace Therapeutics, Inc. (GRCE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 0.75 |
| EV / EBITDA | -0.80 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $309318 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $2.6M | $2.7M | $3.1M | 0 | $119938 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$2.6M | -$2.7M | -$3.1M | 0 | $189378 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $7.2M | $12.1M | $29.4M | $31.9M | $6.6M | $6.9M | $13.5M | $6.4M | $13.5M | $2.4M |
| Selling, General & Admin | $768742 | $3.1M | $4.3M | $16.9M | $10.5M | $12.2M | $11.1M | $9.0M | $10.2M | $8.7M |
| Operating Expenses | $8.0M | $15.3M | $42.5M | $48.8M | $26.1M | $19.5M | $70.5M | $17.4M | $23.8M | $11.1M |
| Operating Income | -$10.5M | -$15.3M | -$34.4M | -$48.8M | -$25.9M | -$19.5M | -$70.5M | -$17.4M | -$23.8M | -$11.1M |
| EBITDA | -$8.0M | -$14.3M | -$36.8M | -$45.9M | -$15.5M | -$19.2M | -$24.5M | -$15.4M | -$23.7M | -$11.1M |
| Interest Expense | $54439 | $371622 | $1.1M | $414177 | $331649 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$10.7M | -$16.7M | -$39.4M | -$51.0M | -$31.1M | -$13.1M | -$70.3M | -$19.9M | -$18.2M | -$9.5M |
| Income Tax | -$121083 | 0 | 0 | 0 | 0 | -$809658 | -$12.9M | -$2.5M | -$4.6M | -$1.7M |
| Net Income | -$10.6M | -$16.7M | -$39.4M | -$51.0M | -$31.1M | -$12.3M | -$57.4M | -$17.4M | -$13.6M | -$7.8M |
| EPS | $-45.67 | $-59.30 | $-46.58 | $-28.78 | $-12.59 | $-2.02 | $-7.72 | $-1.83 | $-1.13 | $-0.47 |
| EPS (Diluted) | $-45.67 | $-59.30 | $-46.58 | $-28.78 | $-12.59 | $-2.02 | $-7.72 | $-1.83 | $-1.13 | $-0.47 |
| Shares Outstanding (Diluted) | $231135 | $364302 | $1.1M | $1.8M | $2.5M | $6.1M | $7.4M | $9.5M | $12.1M | $16.5M |
Price
| Price | $2.14 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVC · ATNM · CALC · LTRN · LVTX · OKUR · PDSB
Explore sector: Healthcare · Biotechnology
More sections of GRCE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks